CRGX

Insider Trades

Name	Value	Action	Price	Current Price
Radhakrishnan AnupSee Remarks $6.8k1.6k shares SellJul 2, 2025 $4.18 --
Radhakrishnan AnupSee Remarks $105k27.4k shares SellMay 14, 2025 $3.84 --
Radhakrishnan AnupSee Remarks $6.5k1.6k shares SellApr 3, 2025 $4.00 --
Chapman GinaDirector, Officer: President & CEO $74k3k shares SellSep 19, 2024 $25.03 --
Chapman GinaDirector, Officer: President & CEO $180k7.2k shares SellSep 18, 2024 $25.09 --
Radhakrishnan AnupChief Financial Officer $40k1.6k shares SellSep 18, 2024 $25.28 --

Trade CRGX

About CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.

CEO: Anup Radhakrishnan
IPO Date: Nov 13, 2023

Market Data

Open: $4.47
High: $4.47
Low: $4.47
Volume: 9.5M
52W High: $25.45
52W Low: $3.00

Valuation

Market Cap: $216M
Enterprise Value: $109M

Financials

Free Cash Flow: $-144M
Revenue: $0
Net Income: $-168M
Cash: $64M
Debt: $29M

Events

EarningsMay 6